| 1 |
33137541 | Targeted inhibition of glutamine metabolism enhances the antitumor effect of selumetinib in KRAS-mutant NSCLC. | 2021 Jan |
2 |
| 2 |
33273059 | AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib. | 2021 Feb |
4 |
| 3 |
33296125 | Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer. | 2021 Apr |
1 |
| 4 |
33405090 | Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinoma. | 2021 Jun |
1 |
| 5 |
32880495 | Treating non-small cell lung cancer with selumetinib: an up-to-date drug evaluation. | 2020 Nov |
1 |
| 6 |
33052075 | Chemotherapeutic effects of MEK kinase inhibitor and BRAF kinase inhibitor on KRAS-mutated human colon cancer cell lines with different microsatellite instability. | 2020 Dec |
1 |
| 7 |
30579838 | Schedule-dependent synergistic effects of 5-fluorouracil and selumetinib in KRAS or BRAF mutant colon cancer models. | 2019 Feb |
2 |
| 8 |
30706361 | Combination of MEK Inhibitor and the JAK2-STAT3 Pathway Inhibition for the Therapy of Colon Cancer. | 2019 Apr |
1 |
| 9 |
30867799 | Dual inhibition of MEK and p38 impairs tumor growth in KRAS-mutated non-small cell lung cancer. | 2019 Mar |
1 |
| 10 |
31200828 | Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219. | 2019 Jul |
1 |
| 11 |
31602313 | Defining subpopulations of differential drug response to reveal novel target populations. | 2019 |
1 |
| 12 |
30042150 | Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer. | 2018 Sep 15 |
1 |
| 13 |
27978579 | Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial. | 2017 Apr 1 |
1 |
| 14 |
28492898 | Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial. | 2017 May 9 |
2 |
| 15 |
28675058 | Selumetinib for the treatment of non-small cell lung cancer. | 2017 Aug |
2 |
| 16 |
29045535 | SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer. | 2017 Dec 1 |
1 |
| 17 |
26666244 | A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer. | 2016 Apr |
1 |
| 18 |
26802155 | Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer. | 2016 Apr |
3 |
| 19 |
26837474 | Study Design and Rationale for a Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Selumetinib in Combination With Docetaxel as Second-Line Treatment in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer (SELECT-1). | 2016 Mar |
1 |
| 20 |
26893312 | Targeting the MEK signaling pathway in non-small cell lung cancer (NSCLC) patients with RAS aberrations. | 2016 Jun |
2 |
| 21 |
27068338 | The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma. | 2016 May |
1 |
| 22 |
27141064 | The molecular pathology of ovarian serous borderline tumors. | 2016 Apr |
1 |
| 23 |
27231576 | A long-term surviving patient with recurrent low-grade serous ovarian carcinoma treated with the MEK1/2 inhibitor, selumetinib. | 2016 |
1 |
| 24 |
27422710 | Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer. | 2016 Oct |
1 |
| 25 |
27467210 | Selumetinib in the treatment of non-small-cell lung cancer. | 2016 Nov |
3 |
| 26 |
28154798 | Activity-Based Proteomics Reveals Heterogeneous Kinome and ATP-Binding Proteome Responses to MEK Inhibition in KRAS Mutant Lung Cancer. | 2016 Jun |
1 |
| 27 |
25322874 | Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer. | 2015 Jan |
1 |
| 28 |
25342139 | BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer. | 2015 Feb |
5 |
| 29 |
25385055 | Selumetinib for the treatment of cancer. | 2015 Jan |
1 |
| 30 |
25516890 | Antitumor activity in RAS-driven tumors by blocking AKT and MEK. | 2015 Feb 15 |
2 |
| 31 |
25667274 | Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial. | 2015 Mar 20 |
1 |
| 32 |
25961376 | Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells. | 2015 Jun 10 |
1 |
| 33 |
26125448 | Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer. | 2015 Jul 14 |
5 |
| 34 |
26567773 | Targeting inhibition of extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) suppresses growth and angiogenesis of gastric cancer. | 2015 Nov 16 |
1 |
| 35 |
24406751 | Novel drugs against non-small-cell lung cancer. | 2014 Mar |
1 |
| 36 |
24716986 | Efficacy and safety of selumetinib compared with current therapies for advanced cancer: a meta-analysis. | 2014 |
1 |
| 37 |
24935174 | Whole genome gene copy number profiling of gastric cancer identifies PAK1 and KRAS gene amplification as therapy targets. | 2014 Nov |
1 |
| 38 |
25342991 | Novel agents in development for advanced non-small cell lung cancer. | 2014 Sep |
1 |
| 39 |
23200175 | Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. | 2013 Jan |
6 |
| 40 |
23414467 | Selumetinib: a promising pharmacologic approach for KRAS-mutant advanced non-small-cell lung cancer. | 2013 Feb |
3 |
| 41 |
24063423 | Selumetinib in advanced non small cell lung cancer (NSCLC) harbouring KRAS mutation: endless clinical challenge to KRAS-mutant NSCLC. | 2013 Jun |
7 |
| 42 |
24130864 | Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models. | 2013 |
2 |
| 43 |
22082529 | Down-regulation of mitogen-inducible gene 6, a negative regulator of EGFR, enhances resistance to MEK inhibition in KRAS mutant cancer cells. | 2012 Mar |
1 |
| 44 |
22173548 | Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models. | 2012 Feb 15 |
2 |
| 45 |
21118963 | MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy. | 2011 Jan 15 |
3 |
| 46 |
21385921 | Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells. | 2011 May 1 |
4 |
| 47 |
21447798 | Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. | 2011 Mar 29 |
3 |
| 48 |
21674991 | A correction to the research article titled: "Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells" by A. S. Little, K. Balmanno, M. J. Sale, S. Newman, J. R. Dry, M. Hampson, P. A. W. Edwards, P. D. Smith, S. J. Cook. | 2011 |
3 |
| 49 |
20923857 | Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer. | 2010 Dec |
3 |
| 50 |
19637312 | Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. | 2009 Nov 15 |
2 |